Supplementary Files
Keywords
Antibodies
Biotechnology
Therapeutics
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Conduct an analysis of the therapeutic efficacy and safety of drugs and therapies derived from modern biotechnology for the treatment of Acute Lymphoblastic Leukemia (ALL). Methods: An integrative review was conducted with a search in the PubMed/MEDLINE, SCOPUS, Web of Science, and Lilacs databases, and studies were selected according to inclusion and exclusion criteria. Results: After the search and selection, 30 articles were selected for full reading, grouped into 3 different categories. Studies conducted with L-asparaginase(L-ASNase) indicated that this drug is used in polychemotherapy regimens, and in some individuals, the administration of native E. coli L-ASNase results in the development of an allergy, requiring its replacement. Monoclonal antibodies have been particularly used in R/R ALL cases, with Inotuzumab Ozogamicin standing out. Finally, CAR-T cell therapy, also used in individuals with R/R ALL, presents a range of adverse events that need to be better understood and carefully monitored. Final considerations: These therapeutic products, derived from these technologies, are safe and effective in the treatment of ALL, as long as their effects are properly monitored, and any potential adverse events are promptly managed.
References
ABREU JAC e ALBUQUERQUE EPA. Use o Biotechnological Drugs and Therapies in the Treatment of Individual with Acuet Lymphoblastic Leukemia: a Scope Review, 2024.
ANVISA. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Gerência-geral de medicamentos e produtos biológicos. Parecer Público de Avaliação do Medicamento. Brasília, 2019; 18. Disponível em: https ://consult as.anvisa.gov.br/#/pareceres/q/?nomeProduto=Besponsa. Acessado em 17 de junho de 2024.
ALBERTSEN BK, et al. Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: A NOPHO ALL2008 randomized study. Journal of Clinical Oncology, 2019; 37(19): 1638–1646.
AL-SALAMA ZT. Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia. Targeted Oncology, 2018; 13(4): 525–532.
ACS. AMERICAN CANCER SOCIETY. Key Statistics for Acute Lymphocytic Leukemia (ALL) - American Cancer Society. 2024. Disponível em: https ://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/about/key-statistics.html. Acessado em 14 junho de 2024.
AN F, et al. Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia. Nature Communications, 2020; 11(1): 5928.
BATTISTEL AP, et al. Allergic reactions to asparaginase: Retrospective cohort study in pediatric patients with acute lymphoid leukemia. Hematology, Transfusion and Cell Therapy, 2020; 3(1): 9–14.
BROWNEEK, et al. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia. Journal of Pediatric Oncology Nursing, 2018; 35(2): 103-109.
CHEN S, et al. Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories from 2020 to 2050. JAMA Oncology, 2023; 9(4): 465–472.
DINNDORF PA, et al. FDA Drug Approval Summary: Pegaspargase (Oncaspar®) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL). The Oncologist, 2007; 12(8): 991–998.
ETTINGER LJ, et al. An open‐label, multicenter study of polyethylene glycol‐L‐asparaginase for the treatment of acute lymphoblastic leukemia. Cancer, 1995; 75(5): 1176–1181.
FREY N e PORTERD. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 2019; 25(4): 123–127.
FURZERJ, et al. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada. JAMA Oncology, 2020; 6(3): 393–401.
HAY KA, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 2019; 133(15): 1652–1663.
HERNANDEZN e BESSONEF. Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies. Journal of Clinical and Translational Hepatology, 2022; 10(3): 486–495.
INABA H, et al. Acute lymphoblastic leukaemia. The Lancet, 2013, 381(9881): 1943–1955.
JABBOUR E, et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage. Cancer, 2018; 124(20): 4044–4055.
JABBOUR E, et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. American Journal of Hematology, 2015; 90 (3): 193–196.
JABBOUR EJ, et al. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer, 2018; 124(8): 1722–1732.
JIANG H, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. American Journal of Hematology, 2019a; 94(10): 1113–1122.
JIANG H, et al. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Annals of Hematology, 2019b; 98(7): 1721–1732.
KANTARJIAN H, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. The Lancet Oncology, 2018; 19(2): 240–248.
KANTARJIAN H, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study. The Lancet Oncology, 2012; 13(4): 403–411.
KANTARJIAN HM, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. The Lancet Haematology, 2017; 4(8): 387–398.
KANTARJIAN HM, et al. Inotuzumab Ozogamicin Versus Standard Care for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2016; 375(8): 740–753.
KANTARJIANH, et al. Blinatumomab versus Chemotherapy for Advenced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017; 376(9): 836–847.
KAUL S, et al. A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia. Cancer Medicine, 2016; 5(2): 221–229.
MA Y, et al. A phase I study of CAR-T bridging HSCT in patients with acute CD19+ relapse/refractory B-cell leukemia. Oncology Letters, 2020; 20(4): 20.
MALARD F e MOHTY M. Acute lymphoblastic leukaemia. The Lancet, 2020; 395(10230): 1146–1162.
MARKS DI, et al. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. The Lancet Haematology, 2022; 9(4): 262–275.
MAUDESL, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 2018; 378(5): 439–448.
MEANY HJ, et al. Feasibility study of a novel Experimental induction protocol combining B43-PAP (anti-CD19) immunotoxin with standard induction chemotherapy in children and adolescents with relapsed B-lineage ALL: A report from the children’s oncology group. Journal of Immunotherapy, 2015; 38(7): 299–305.
MICHOT JM, et al.Immune-related adverse events with immune checkpoint blockade: A comprehensive review. European Journal of Cancer, 2016; 54: 139–148.
MS. MINISTÉRIO DA SAÚDE - AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Resolução - RE No560, de 18 de fevereiro de 2022. Brasília, 2022. Disponível em: https ://www.in.gov.br/en/web/dou/-/resolucao-re-n-560-de-18-de-fevereiro-de-2022-382329255. Acessado em 14 de junho de 2024.
MS. MINISTÉRIO DA SAÚDE - INSTITUTO NACIONAL DE CÂNCER. Atlas On-line de Mortalidade. 2024. Disponível em: https ://mortalidade.inca.gov.br/MortalidadeWeb/pages/Modelo01/consultar.xhtml. Acessado em 14 junho de 2024.
NAGURA E, et al. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 1994; 33(5): 359–365.
OUZZANI M, et al. Rayyan—a web and mobile app for systematic reviews. Systematic Review, 2016; 5: 210.
PAGE MJ, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. The British Medical Journal, 2021; 372: 71.
PANOSYAN EH, et al. Asparaginase Antibody and Asparaginase Activity in Children with Higher-Risk Acute Lymphoblastic Leukemia: Children’s Cancer Group Study CCG-1961. Journal of Pediatric Hematology/Oncology, 2004; 26(4): 217–226.
PATEL B, et al. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: Toxicity data from the UKALL14 trial. Leukemia, 2017; 31(1): 58–64.
PEDROSAF e LINS M. Leucemia linfóide aguda: uma doença curável Revista Brasileira de Saúde Materno Infantil, 2002; 2(1): 63–68.
PIETERS R, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: A randomized phase 2 clinical trial. Blood, 2008; 112(13): 4832–4838.
PLACE AE, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): A randomised, open-label phase 3 trial. The Lancet Oncology, 2015; 16(16): 1677–1690.
RAETZEA, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A children’s oncology group pilot study. Journal of Clinical Oncology, 2008; 26(22): 3756–3762.
RAETZEA, et al. Re-Induction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL): Phase II Results from Children’s Oncology Group (COG) Study ADVL04P2. Pediatric Blood & Cancer, 2015; 62: 1171–1175.
RAPONI S, et al. A. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: Analysis of 552 cases. Leukemia and Lymphoma, 2011; 52(6): 1098–1107.
SMITH OP e HANN IM. Clinical Features and Therapy of Lymphoblastic Leukemia. In: ARCECIRJ, HANN IM, SMITHOP. (orgs). Pediatric Hematology. Third Edit.: Blackwell Publishing, 2006; 450–481.
SUZMAN DL, et al. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. Liver International, 2018; 38(6): 976–987.
TERWILLIGERT e ABDUL-HAYM. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal, 2017; 7(6): 577.
THOMASDA, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome - Negative precursor B-lineage acute lymphoblastic leukemia. Journal of Clinical Oncology, 2010; 28(24): 3880–3889.
TURCOTTE LM, et al. Cost of Pediatric Acute Lymphoblastic Leukemia Care in the Current Treatment Era. Bood, 2021; 138(1): 663.
TURTLE CJ, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. Journal of Clinical Investigation, 2016; 126(6): 2123–2138.
VOLLMAR BS, et al. Calicheamicin antibody-drug conjugates with improved properties. Molecular Cancer Therapeutics, 2021; 20(6): 1112–1120.
WIDJAJANTO PH, et al. L-asparaginase: Long-term results of a randomized trial of the effect of additional 3 doses during consolidation treatment in the indonesian WK-ALL-2000 protocol. Journal of Pediatric Hematology/Oncology, 2013; 35(8): 597–602.
ZENY e YEHMM. Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy. Seminars in Diagnostic Pathology, 2019; 36(6): 434–440.
ZHANG N, et al. Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity. Journal of Immunotherapy, 2022; 45(9): 396–406.